Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based CEO’ operating in the Medical space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Rakesh Kapoor
CEO of Reckitt
Rakesh Kapoor joined Reckitt & Colman in 1987, serving in various roles including Regional Sales Manager, North India, General Manager, Indian Southern Region and Regional Marketing Director, South Asia. In 1999, he was appointed Global Category Director, Pest Control. Following the merger, he assumed the role of, Senior Vice President, Home Care. He was appointed SVP, Regional Director, Northern Europe in 2001 and in July 2006, he was promoted to EVP, Category Development. Rakesh became CEO in September 2011
Follow Rakesh Kapoor:
About Reckitt: Reckitt Benckiser Group is a consumer goods company makes health, hygiene and home products.
_______
Yusuf Sherwani
Co-Founder & CEO of Quit Genius
Yusuf is the Co-Founder and CEO of Quit Genius. He is a Y Combinator alumni and was featured by Fast Company’s as one of their Most Creative People of 2019 as well as Forbes’ 30 Under 30 List of 2018.
Follow Yusuf Sherwani:
About Quit Genius: Quit Genius is pioneering digital therapeutics for multiple addictions.
Andre Chow
Co-Founder & Co-CEO of Digital Surgery
Andre is a General Surgeon, Web coder, UX designer and all-round hacker. He has a BSc in Surgical Technology, a PhD in Tissue Engineering and leads Operations & Product. When not in the lab, Andre spends his spare time playing a variety of sports, and trying to push his french bulldog off the sofa.
Follow Andre Chow:
About Creative Destruction Lab (CDL), Digital Surgery, Medtronic, Touch Surgery: Digital Surgery is a privately-held pioneer in surgical artificial intelligence (AI), data and analytics, and digital education and training
Kevin Lee
Chief Executive Officer of Bicycle Therapeutics
Kevin Lee, Ph.D., MBA, is chief executive officer of Bicycle Therapeutics. Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programmes across the full spectrum of research and development, established Pfizer’s rare disease strategy, conceptualized and implemented the company’s gene therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GlaxoSmithKline (GSK) and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, he lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions. Kevin studied pharmaceutical sciences at Nottingham University followed by a Ph.D. in pharmacology at Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research Unit in Cambridge, U.K. Kevin is an author on over 100 peer-reviewed scientific publications, has an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick.
Follow Kevin Lee:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Emmanuel Ligner
President & CEO, Life Sciences of GE Healthcare
Emmanuel joined GE Healthcare in April 2008, following its acquisition of Whatman International Plc. Since 2008, Emmanuel has held various positions in GE Healthcare Life Sciences. Working both in the UK and in the US, he managed the North America BioProcess business. In January 2012, Emmanuel took charge of the Commercial part of the then Life Sciences business, across EMEA, later expanding his role to include global commercial leadership of BioProcess. In January 2016, Emmanuel was name General Manager of the Core Imaging business which he held until he was named President and CEO of Life Sciences In July 2017. Emmanuel first entered the biopharma industry in Japan, joining Ostuka Pharmaceutical International Ltd as a Medical Representative in Tokyo. After five years in Ostuka in various roles, Emmanuel joined Abbott Japan, occupying positions such as Marketing Director Diagnostic Division and Commercial Director Diabetes Care Division. After 10 years in Japan, Emmanuel moved to the UK as Vice President Sales & Marketing Europe for Whatman International Plc.
Follow Emmanuel Ligner:
About Cytiva, GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Jan Makela
President and CEO, Imaging at GE Healthcare of GE Healthcare
Jan Makela is the President & CEO of GE Healthcare Global Services. Appointed in December 2017, he oversees the global development and execution of GE Healthcare’s service solutions and operations around the globe.
Follow Jan Makela:
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Kieran Murphy
President & CEO of GE Healthcare
Kieran Murphy is President and CEO of GE Healthcare, a $20 billion business unit of General Electric that provides transformational medical technologies and solutions to the global healthcare industry. GE Healthcare supports customers in over 100 countries with a broad range of services and systems, from diagnostic imaging and healthcare IT through to molecular diagnostics and life-sciences. Prior to this, Kieran was President and Chief Executive Officer of GE Healthcare Life Sciences, a $3.7 billion molecular medicine business that provides a broad range of industry-leading technologies and services for drug discovery, pre-clinical and clinical development and biopharmaceutical manufacturing, as well as molecular tools for diagnostics, therapy selection and treatment monitoring in patient care. Kieran was appointed CEO in May 2011 and oversaw significant revenue growth and geographic expansion of the molecular medicine business. Kieran joined GE Healthcare in 2008 from Whatman plc, a $230 million global supplier of filters and membranes for laboratory research, life sciences and medical diagnostic applications. Kieran has over twenty years’ experience in the global life sciences and biotechnology industry, beginning his career with Janssen Pharmaceutical, a division of Johnson and Johnson, followed by leadership roles with Mallinckrodt, veterinary medicines provider Vericore, Novartis, Adprotech, ML Laboratories and Innovata plc.
Follow Kieran Murphy:
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Jean-luc Bressard
CEO of Hextransforma Healthcare
Social equality campaigner and entrepreneur
Follow Jean-luc Bressard:
About Dolerite Ltd, Hextransforma Healthcare, Time to Shine Kids: Telemedicine and digital healthcare solution provider. Owner of the Brit-Med.com medical tourism platform
Peter Hames
Co-Founder & CEO of Big Health
Peter Hames is CEO of Big Health, a digital medicine company he co-founded with clinical psychologist Prof Colin Espie (University of Oxford). Big Health creates automated behavioral medicine programs fuelled by tracked data, and was inspired by Peter’s difficulty in getting access to evidence-based non-drug solutions to his own insomnia. Big Health’s first product, Sleepio, is a digital sleep improvement program featuring personalized Cognitive Behavioral Therapy (CBT) techniques, delivered by virtual animated sleep expert The Prof and his narcoleptic dog Pavlov. In the world’s first placebo-controlled randomised trial for an intervention of its kind, Sleepio was shown to be comparable in effectiveness to face-to-face therapy.
Follow Peter Hames:
About Big Health, Lucky Voice, NHS England, Sleepio: Big Health is a digital therapeutics company operating a healthcare portal to offer behavioral programs for mental health issues.
John Lucas
Chief Executive Officer of Oxford Cannabinoid Technologies
John is a pharmaceutical executive with over 20 years of experience, having previously held executive level management positions at Cizzle Biotechnology (as CEO), Silence Therapeutics (as General Counsel) and Ilika Plc (Vice President, Intellectual Property) with other experience at the National Cancer Institute and Boehringer Ingelheim Pharma. John has also run his own consulting business where he assisted clients with business and legal/patent matters in biotech-pharma. His experience includes deal-making, corporate and product strategy, operations, and patents. John also has a wide range of subject matter experience including small molecule pharmaceuticals (including cannabinoids), RNA therapy, biologics, and diagnostics. John holds a law degree (JD) from George Washington University, a doctorate in molecular genetics from The Ohio State University, and a Master’s and Undergraduate degree in microbiology from Ohio University.
Follow John Lucas:
About Oxford Cannabinoid Technologies: OCT is a biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.
Alex Blyth
CEO of LIfT BioSciences
Serial entrepreneur with 15 years’ experience in commercialising biopharma assets and strategy consulting, having advised teams and led the strategic planning on the launch of over 50 assets. Founded the company after losing his mother to Pancreatic Cancer.
Follow Alex Blyth:
About LIfT BioSciences, NGX: LIfT BioSciences is a socially-minded Biotech start-up that develops a portfolio of potentially life-saving immuno-oncology cell therapies.
Peter Ward
CEO and Co-Founder of Humanity
Peter Ward is a Co-Founder and Chief Executive Officer at Humanity.
Follow Peter Ward:
About Humanity: Humanity is a healthcare company that aims to extend the healthspan of humanity.
Henrik Hagemann
CEO and Co-Founder of Puraffinity
Follow Henrik Hagemann:
About Puraffinity, Tech London Advocates: Puraffinity develops precision materials to target chemicals, with an initial focus on PFAS in water
Dipankar Bhattacharjee
President & CEO: Generics Europe of Teva Pharmaceutical Industries
Mr. Dipankar Bhattacharjee was appointed President and CEO, Generics Europe in April 2013. Mr. Bhattacharjee joined Teva as Chief Executive Officer, Teva UK Limited in 2009. Prior to joining Teva, he served 15 years at Bausch + Lomb in various senior roles, including Vice President, Commercial in both Europe and Asia-Pacific regions, and Corporate Vice President and President, Asia Pacific Region. Mr. Bhattacharjee began his career at Nestlé SA and Bank of America. Mr. Bhattacharjee received a BA in Economics from St. Stephens College, University of Delhi, and a Masters degree in Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Mumbai.
Follow Dipankar Bhattacharjee:
About Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
Gregg Sando
Founder & former Chief Executive Officer of Kuur Therapeutics
Gregg Sando is the founder and CEO of Cell Medica. After a career in investment banking based both in London and New York, he completed his Immunology MSc degree at the medical school of Imperial College. Recognizing the significant progress taking place in the field of cellular immunotherapy, Gregg formed Cell Medica in cooperation with a small group of the leading clinicians and immunologists who were pioneering this new mode of medical treatment. (B.A. Biochemistry, Harvard University; M.B.A. University of Chicago; MSc Immunology, Imperial College London).
Follow Gregg Sando:
About Kuur Therapeutics: Kuur Therapeutics is committed to transforming the lives of patients with cancer & is leading the development cell therapies.
Emil Hewage
Co-Founder & CEO of BIOS
Emil’s academic background is as a PhD researcher in computational neuroscience and machine learning. He brings knowledge of neural signalling and signal processing with over 7 year’s industrial & academic R&D experience. He has previously developed medical devices with Siemens Healthcare and Sphere Medical as well as having held roles in finance and medical and cleantech startups.
Follow Emil Hewage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Sandeep Bansal
Founder & CEO of Medic Creations
Dr Bansal graduated from Imperial College London with a MSc in Paediatrics and Child Health. In 2013 he started his General Practitioner training at Oxford Deanery where he was also Trainee Lead, representing Oxford Deanery for the Associates in Training (AiT) committee in their quarterly meetings at Royal College of General Practitioners. From his professional experience and feedback from his peers, DrBansal raised the concerns of poor Information Governance (IG) compliance around sharing patient dataat AiT meetings. With the AiT board’s response of their inability to offer an alternative solution, Dr Bansalcarried out a survey to understand the extent of the problem in 2014. The survey for his 180 colleagues went viral and he received 2050 responses confirming the poor IG compliance practice, predominantly around the use of WhatsApp. In 2014 he set up Medic Creations and created the innovative app MedicBleep to enable secure and reliable clinical communication for primary, secondary and community care. With enabling communication across healthcare organisations and professionals, Medic Bleep empowerstrue interoperability, the future of healthcare management and innovation. Medic Creations was selected for Web Summit Alpha 2015 and is listed in the Journal of mHealth’s top100 Global Digital Companies for 2016 and 2017.
Follow Sandeep Bansal:
About Bennett Coleman and Co Ltd, Harvard Medical School, Medic Creations, shl.vc: Revolutionising Communications in Healthcare
Chris Edson
Co-founder & CEO of Second Nature
Christopher Edson CEO & Founder of EU Top 50 Startup, Forbes 30 Under 30
Follow Chris Edson:
About Second Nature: Second Nature is a digital programme that helps people lead healthier lives
Nader Alaghband
Co-Founder & CEO of Ampersand Health
Follow Nader Alaghband:
About Ampersand Health: Ampersand creates innovative digital medicines for complex long term conditions, using behavioural and data-science.
David MacMurchy
Chief Executive Officer of Lightship
David MacMurchy is the Chief Executive Officer at Lightship.
Follow David MacMurchy:
About Lightship: Lightship is a provider of enterprise-level and direct-to-patient clinical research solutions for decentralized clinical trials.
Abdullah Albeyatti
CEO & Co-Founder of Medicalchain
Dr Albeyatti graduated from Imperial College London as a doctor in 2011. He has always had a passion for innovation and problem solving and has developed solutions to inefficiencies he found whilst working in the UK National Health Service. In 2016 he co-founded Medicalchain, initially as Discharge Summary – an application used in hospitals to generate accurate medical reports on patients, before they are discharged. Dr Albeyatti’s career in medicine started with surgical training in London and has moved on to general practice with a view to continuing his ENT passion and furthering his management aspirations. He continues to work in Accident and Emergency to sharpen his clinical skill set.
Follow Abdullah Albeyatti:
About dischargesummary.co.uk, Medicalchain, MyClinic, NHS, NHS England: Medicalchain is a decentralized platform that enables secure, fast and transparent exchange and usage of medical data.
Emi Gal
Co-founder & CEO of Ezra AI
Emi Gal is a co-founder of Brainient, a video advertising technology company. Prior to launching the startup in 2009, Gal started two other companies and was involved with various technology and internet startups, including Skimlinks (UK), eOk (Romania) and SkinScan (Romania). Gal occasionally speaks at various entrepreneurship and technology events, writes for The Telegraph and TechCrunch Europe, and has a strong interest in technology and education. He is also a board director on the Board of Romanian seed fund, Digital Catalyst Fund. He has been named in Forbes Romania Top 30 Under 30 (2012) and SquareMile Magazine’s Top 30 Under 30 (2011), and was the Seedcamp winner in 2009. Gal loves experiments, tennis, swimming, books and chocolate.
Follow Emi Gal:
About Ezra AI, Zeno Wearables: Ezra AI provides early cancer detection by combining advanced medical imaging technology and AI technology.
Sokratis Papafloratos
CEO of Numan
Sokratis Papafloratos works as a Founder and CEO at Togethera. Previously CEO & co-founder of TrustedPlaces, acquired by Yell Group in 2010. Engineering degree from York University.
Follow Sokratis Papafloratos:
About Numan, TrustedPlaces: Numan: Helping Your Health Wherever We Can
Hannah Sore
Founder and CEO of PharmEnable
Follow Hannah Sore:
About PharmEnable: PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery.
John E. Milad
CEO & Founder of Quanta
John E. Milad is a global healthcare executive, board member, investor, speaker and author. He has a career spanning over 25 years, with experience working in various senior positions in the healthcare sector, including NBGI Ventures, Atlas Venture, Nitec Pharma and Nomura. Currently, John is Chief Executive Officer and founding board member at Quanta Dialysis Technologies, where he recently raised $245m in Series D funding. An executive with international experience in building and growing successful healthcare companies, John had the vision and belief that core technology of managing fluidics on a disposable cartridge could be developed into a portable hemodialysis device with the potential to address multiple unmet needs in the $93 billion global dialysis market. John is a regular speaker and panelist at global medtech and investment conferences and has co-authored 4 peer-reviewed papers.
Follow John E. Milad:
About NBGI Ventures, Quanta: Quanta develops an advanced haemodialysis systems for use in the home and clinic.
Ali Rezaei Haddad
CEO and Founder of NeuroNav
Ali is a neurosurgical resident in London and an NHS Clinical Entrepreneur. Prior to this, he completed his Academic Foundation Training in the Medical Sciences Division at the University of Oxford undertaking research in the field of neuroimaging. He graduated with first class honours in Neurosciences BSc at Imperial College London, and he holds honorary research positions at the University of Oxford and St George’s Medical School. Ali co-founded the internationally acclaimed GoodSAM app used by the NHS, in which clinically trained individuals sign up as volunteers to respond to life-threatening emergency calls. He also directed and curated the Imagining the Future of Medicine at the Royal Albert Hall in partnership with TEDMED, attended by a live audience of 5,000 people. Inspired by the lack of user friendly and affordable neuronavigation solutions worldwide, he founded NeuroNav to democratise access to neurosurgery navigation solutions.
Follow Ali Rezaei Haddad:
About Imperial College Healthcare NHS Trust, NeuroNav: An augmented reality neuronavigation platform powered by computer vision and machine learning.
Sina Habibi
CEO of Cognetivity Neurosciences
Sina Habibi is the CEO at Cognetivity Neurosciences.
Follow Sina Habibi:
About Cognetivity Neurosciences: Cognetivity Neurosciences is a Platform technology for early, rapid and easy detection of dementia.
Chas Taylor
Chief Executive Officer & Chairman of Respiratory Motion
Mr. Taylor has over 30 years of experience in the medical technology industry. Recently he was the CEO of Veryan Medical, a Co-founder and Director of Novate Medical, and a Director of BrightWater Medical. All three of these companies were acquired in the last three years. Previously, Mr. Taylor was the Co-founder of MedNova, which was acquired by Abbott Laboratories. Prior to founding and leading these companies, he had a long career with Bard Cardiovascular and General Surgical products where he had roles of increasing responsibility in general management and international sales and marketing.
Follow Chas Taylor:
About : Respiratory Motion ExSpiron is FDA and CE Mark cleared and non-invasively measures minute ventilation, the fundamental unit of breathing.
Carina Cunha
Co-Founder & CEO of Be Nosy
Carina is a business strategist and inventor of Nosy with passion for science, sales and marketing. In her former role as MD and Launcher of Crimson Education Europe, she created sales, marketing and service delivery teams from scratch, achieving millions in ARR and 150%+ YoY growth. Prior to working with startups Carina was corporate strategist at JPMorgan, Strategy Consultant at Accenture, Investment Banker at Credit Suisse, and a fashion model with Elite. Carina is also an innovation and commercial consultant through Meta Strategy and Founders Intelligence where she helps startups and scale-ups find product-market fit and corporates build new revenue lines. She has a B.A. from Columbia University and PgD. from the University of Edinburgh.
Follow Carina Cunha:
About Be Nosy: Nosy is a MedTech startup developing wearable air filter and air pollution tracking network.
Graeme L. Smith
Chief Executive Officer of Lightpoint Medical
Graeme L. Smith is the Chief Executive Officer at Lightpoint Medical.
Follow Graeme L. Smith:
About Lightpoint Medical: Lightpoint Medical, a medical device company, develops intra-operative imaging technology that can detect cancer during surgery.
James Noble
Founder & CEO of Adaptimmune
James Noble has served as our full-time Chief Executive Officer since March 2014 and part-time CEO from July 2008 to March 2014 and is one of our co-founders. From July 2008 until March 2014, Mr. Noble was also part-time CEO of Immunocore. Mr. Noble has 24 years of experience in the biotech industry. He has held numerous non-executive director positions, including at CuraGen Corporation, PowderJect Pharmaceuticals plc, Oxford GlycoSciences plc, MediGene AG, and Advanced Medical Solutions plc. Mr. Noble is also Deputy Chairman of GW Pharmaceuticals plc and a non-executive director of Immunocore Limited. Mr. Noble is qualified as a chartered accountant with Pricewaterhouse Coopers and spent seven years at the investment bank Kleinwort Benson Limited, where he became a director in 1990. He then joined British Biotech plc as Chief Financial Officer from 1990 to 1997. Mr. Noble was previously Chief Executive Officer of Avidex Limited, a privately held biotechnology company that was our predecessor, from 2000 to 2006. Mr. Noble holds an MA from the University of Oxford.
Follow James Noble:
About Adaptimmune, Advanced Medical Solutions, Curagen Corporation, MediGene, Oxford GlycoSciences, PowderJect Pharmaceuticals: Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
Yiannis Kiachopoulos
CEO, Co-Founder of Causaly
Follow Yiannis Kiachopoulos:
About Causaly: Causaly is teaching computers to read all knowledge in Biomedicine
Tess Cosad
Co-Founder & CEO of Bea Fertility
Tess Isabelle Cosad is the Chief Executive Officer and Co-Founder of Bea Fertility.
Follow Tess Cosad:
About Bea Fertility: Bea Fertility is a monthly subscription program that provides users with at-home fertility treatment and ovulation tracking.
Zubair Ahmed
CEO & Founder of MedicSpot
Follow Zubair Ahmed:
About MedicSpot: MedicSpot gives patients convenient and quick access to healthcare using the latest advancements in telemedicine
Steve Miller
CEO of KoolZone
Follow Steve Miller:
About KoolZone: KoolZone offers real-time remote monitoring solutions for the hospitality and healthcare industry.
Richard Vincent
CEO & Co-Founder of FundamentalVR
Richard has 20+ years’ experience of building international businesses and has throughout his career sought opportunities for positive market disruption through technological application. It was this desire that led him to co-found FundamentalVR to help address an age-old problem for the medical market; how to create safe, realistic, measurable spaces to learn and develop skills. In his role as CEO Richard is responsible for building a world class team of medical, learning and technologist who together can realise the company’s ambition of creating the world’s first global, haptically enabled, low cost ‘flight simulator for surgeons’.
Follow Richard Vincent:
About Fundamental Surgery, FundamentalVR: FundamentalVR delivers VR haptic ‘flight simulators’ for surgery creating a safe, measurable & repeatable space to refine to refine skills.
Michalis Papadakis
CEO & Co-Founder of Brainomix
Dr Michalis Papadakis is the CEO and co-founder of Brainomix. He leads the management team, commercial strategy, fund raising, and corporate partnerships. He has grown the company from the ground up, building the company’s global presence and has raised over £15 million of private investment and public funding. When he founded Brainomix he was the Scientific Director of the preclinical stroke lab at the University of Oxford. He has a BSc Honours in Biochemistry from Imperial College London and a PhD in neurosciences from UCL School of Pharmacy. He has been an invited speaker at international scientific and innovation conferences
Follow Michalis Papadakis:
About Brainomix: Brainomix specializes in the creation of AI-powered imaging biomarkers that enable precision medicine for better treatment decisions
Global CEO & Co-Founder of Andiamo
Follow Naveed Parvez:
About Andiamo, UnLtd: Custom medical wearables platform
Ian Nicholson
Chief Executive Officer of F2G
Ian joined Advent in 2012 from Chroma Therapeutics Limited, a privately held oncology-focussed R&D company, where he served as Chief Executive Officer for eight years. Prior to joining Chroma, Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK’s largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. Ian has held a variety of senior commercial positions with Oxford Asymmetry International plc, Lonza AG and Amersham International plc and currently sits on the Boards of Consort Medical plc, Clinigen Group plc and is Non-Executive Chairman of Bioventix plc. Ian holds a B.Sc. (Hons.) degree from University College London and an MBA from Boston University. Ian is CEO of F2G Ltd and an advisor to NeRRe Therapeutics.
Follow Ian Nicholson:
About Advent Life Sciences, Amersham International, F2G: F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
Nick Morrell
CEO and co-Founder of Morphogen-IX
Nick is the British Heart Foundation Professor of Cardiopulmonary Medicine at the University of Cambridge, based in the Department of Medicine. He has 25 years of experience working in the field of pulmonary arterial hypertension (PAH), and is the Research Director of the National Pulmonary Hypertension Service at Papworth Hospital. His research spans clinical translational studies, experimental medicine, genetics, cell and molecular biology and preclinical models of disease. He has published over 200 papers in this field and is an internationally recognised authority on the pathobiology of PAH.
Follow Nick Morrell:
About Morphogen-IX, Papworth Hospital, University of Cambridge: MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins
Atul Devani
CEO of The GP Service
A serial entrepreneur, Atul has held a number of senior positions in software technology companies operating in various sectors including finance, mobile, telecoms, food & drink, health and pharmaceuticals.
He was founder and chief executive officer of AIM listed United Clearing Plc, which was sold to BSG in 2006 for £25m. He became CEO of BSG wireless which in 2008 was then sold to nasdaq listed Syniverse Tecnologies for $290m. Atul is currently CEO of leading online UK Healthcare provider “The GP Service” and Chairman of a Venture Capital Trust at Maven Capital and an investor in a number of private companies.
He is also a mentor of entrepreneurs at the Company of Information Technologists in the City of London. Atul has a First Class Honours Degree in Electronic Engineering from Bangor University.
Follow Atul Devani:
About The GP Service: The GP Service is a provider of online services for general medical consultations and prescriptions.
Tej Virk
Chief Executive Officer of Akanda
Tej Virk currently works as the Chief Executive Officer for Akanda.
Follow Tej Virk:
About Akanda: Akanda is a medical company that produces medical cannabis for patients.
Rahil Vora
CEO of Revital
Follow Rahil Vora:
About Revital: Revital is an independent company with a mission to care for the wellbeing and health of our customers.
Jodie Fam
Chief Executive Officer of AblaCare
Jodie brings more than 20 years of medical device experience leading early stage medical device product development, market access and commercialization for major medtech companies and several venture-backed startups. She has been instrumental in bringing a number of early-stage, paradigm-shifting medical technologies to market in diverse and competitive environments. Jodie has held top management roles at Concentric Medical (acquired by Stryker), Medina Medical (acquired by Medtronic), Route 92 Medical and CardioKinetix, as well as senior sales and marketing positions with Johnson & Johnson, Guidant Corporation and Mallinckrodt Medical.
Follow Jodie Fam:
About AblaCare, CardioKinetix, Q’Apel Medical: AblaCare develops an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility.
David Atkins
CEO of Congenica
Dr Atkins has over 25 years’ experience as a global leader in a broad range of diagnostics and healthcare businesses. He has held senior positions in R&D, business development, operations and sales and marketing. He has extensive commercial experience in markets in North America, EMEA, Asia and Latin America. Prior to joining Congenica, Dr Atkins was CEO of Synevo, a clinical diagnostic laboratory service business operating across Germany and Eastern Europe. Past roles also include global head of the Advanced Staining pathology business unit for Leica Biosystems, a Danaher Company. Dr Atkins also has over 20 years’ experience with Johnson & Johnson’s Medical Device and Diagnostic businesses in R&D and business development and in senior international commercial roles.
Follow David Atkins:
About Congenica: Congenica is a biotechnology company that provides a diagnostic decision support platform.
Paolo Pieri
CEO of Circle Health
Paolo Pieri is the CEO of Circle. He joined as the Chief Financial Officer in November 2010 after spending five years at lastminute.com. Paolo has a bachelor of accountancy from Glasgow University and is a member of the Chartered Institute of Accountants for Scotland.
Follow Paolo Pieri:
About Circle Health: Circle Health is a provider of health care service with investigation and treatment of diseases.
Elena Mustatea
CEO of Bold Health
Elena is an Associate at Atomico. As part of our London team, she focuses on sourcing and evaluating investment opportunities, as well as supporting Atomico and its portfolio companies on operational projects and research. Before joining Atomico, Elena worked in investment banking at J.P. Morgan in London, where she advised various EMEA internet, telecoms, media and technology companies in financing and M&A processes. Elena started her career as a management consultant with Oliver Wyman in Dubai covering Middle Eastern telecoms and public sector companies, with a focus on strategy, business planning and risk management projects. Elena holds a Bachelor of Arts in Economics from Dartmouth College in the US, and studied abroad in Germany, France, and Italy.
Follow Elena Mustatea:
About Bold Health: Bold Health is a specialty telemedicine company that offers best-in-class integrative care for Gastrointestinal (GI) conditions.
Ali Moiyed
CEO & Founder of Aerobit Health
Follow Ali Moiyed:
About Aerobit Health: Breathing New Life Into Asthma Care
Krishan Ramdoo
CEO and Founder of Tympa Health Technologies LTD
Krishan Ramdoo is the CEO and Founder of TympaHealth Technologies.
Follow Krishan Ramdoo:
About Tympa Health Technologies LTD: TympaHealth are a team of doctors and technology experts united in their vision of helping the world to hear.
Yeshwanth Pulijala
Founder & CEO of Scalpel
Follow Yeshwanth Pulijala:
About Scalpel: Scalpel provides a platform to optimize surgical procedures in clinics and hospitals.
Thang Vo-Ta
CEO & Co-Founder of Callaly
Co-founder & CEO at Callaly.Thang is a graduate of MIT and started his career in Goldman Sachs in NYC & London.
Follow Thang Vo-Ta:
About Callaly: Callaly is a period care company that develops and manufactures innovative feminine care products.
Paweł Sieczkiewicz
Co Founder & CEO of Telemedi
Graduate of Warsaw University of Technology, experienced project manager (web/mobile apps), php programmer. Founder of an SSF software house. 2x champion of Poland in kickboxing.
Follow Paweł Sieczkiewicz:
About Telemedi: Trusted partner in digital healthcare
Ian Braithwaite
CEO & Co-Founder of Habitual
Ian Braithwaite is the CEO and Co-Founder at Habitual.
Follow Ian Braithwaite:
About Habitual: Digital therapeutics & nutritional treatment for type 2 diabetes reversal.
Emilio Sanz Pereiras
CEO of Acurable
Emilio is a serial entrepreneur and leads Acurable’s strategy, operations and commercialisation activities. Emilio spent the last 15 years building 3 successful start-ups across Europe and Asia, where he learned first hand how to successfully commercialise highly innovative technologies and how to to scale start-up operations in both B2B and B2C industries. Originally from Spain, Emilio holds a MSc in Electrical Engineering from Telecom ParisTech, a MSc in Computer Science from the Polytechnic University of Madrid and an MBA from London Business School.
Follow Emilio Sanz Pereiras:
About Acurable: The first wearable medical device able to accurately diagnose and manage respiratory conditions at home
Soren Krogsgaard Thomsen
Co-Founder, CEO and Managing Director of BioMe Oxford
Soren is a medical scientist at the University of Oxford, with a background in the natural sciences and genetics research. He previously worked as a consultant for pharma and OBR consulting, and has published on his experiences as an academic entrepreneur. Soren’s current research is focused on translating large-scale genetic data into mechanisms for disease to inform new therapeutic strategies. He dreams of one day enabling similar population-wide microbiome studies using the platform technology under development at BioMe Oxford Ltd.
Follow Soren Krogsgaard Thomsen:
About BioMe Oxford, Vertex Pharmaceuticals: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Joel Gibbard
CEO of Open Bionics
Joel Gibbard is the founder of Open Bionics and the inventor of the world’s first and most advanced 3D printed robotic hand prosthetic. Joel has won multiple awards for engineering, innovation, and entrepreneurship. Joel was recently named ‘Britain’s Design Engineer of the Year,’ and awarded the Limbless Association’s ‘Prosthetic Innovation of the Year’ award. The roboticist is based inside of the Bristol Robotics Laboratory and is committed to keeping his robotic hands open source.
Follow Joel Gibbard:
About Open Bionics: Open Bionics is a robotics company creating affordable 3D-printed bionic hands for amputees, researchers and makers.
Keith Blundy
CEO of Storm Therapeutics
Follow Keith Blundy:
About Storm Therapeutics: Targeting pathways that modify RNA to deliver novel cancer therapeutics
Edward Ungar
Co-Founder & CEO of Pharmacierge
Edward Ungar is a Co-founder at Pharmacierge.
Follow Edward Ungar:
About Pharmacierge: The free e-prescribing service chosen by Private GPs and Consultants to deliver medication to their patients nationwide
Harry lamble
CEO of Sense Biodetection
Follow Harry lamble:
About Sense Biodetection: Sense Biodetection Limited is a molecular diagnostics company .
Chris Martin
CEO of ADC Therapeutics
Chris Martin, DPhil, is the former CEO and co-founder ADC Therapeutics, a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates.
Follow Chris Martin:
About ADC Therapeutics: ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
David Sibbald
CEO and Co-Founder of Aridhia Informatics
David Sibbald is the co-founder and CEO of Aridhia, a health data science company which develops and runs a cloud-enabled Digital Research Environment for clinical research, precision medicine and healthcare applications. David is the Founder and Trustee of the Kate MacAskill Foundation, a charitable organisation providing education, care and micro-enterprise funding for children and young adults in the developing world and is Chairman of the Johari Foundation. He has been awarded honorary doctorates from Glasgow University, Glasgow Caledonian University, the University of Paisley and the University of Strathclyde for services to Scottish science and philanthropy. He is a Fellow of the Royal Society of Edinburgh, Scotland’s National Academy of Science and Letters. In the 2010 New Year Honours List, David was awarded an OBE for charitable services in Scotland and overseas.
Follow David Sibbald:
About Aridhia Informatics, Kate MacAskill Foundation: Aridhia informatics provides biomedical informatics and analytics services to improve the management of chronic diseases.
Katerina Spranger
Founder and CEO of Oxford Heartbeat
Katerina is the Fellow of the Royal Academy of Engineering. She holds a PhD in Biomedical Engineering from the University of Oxford and was previously a researcher in AI at the Sony Computer Science Laboratory in Paris.
Follow Katerina Spranger:
About Oxford Heartbeat, Royal Academy of Engineering: Oxford Heartbeat makes cardiovascular surgery more accurate and safe.
AF_initDataCallback({key: \’ds:1\'” alt=”” class=”wp-image-14850″ width=”154″ height=”152″/>Mike Westby
CEO of Centauri Therapeutics
Mike Westby is the Chief Executive Officer at Centauri Therapeutics Limited since September 2015.
Follow Mike Westby:
About Avvinity, Centauri Therapeutics: Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of life threatening diseases.
Mark Wilson
CEO of The Cochrane Collaboration
Mark Wilson is CEO at The Cochrane Collaboration.
Follow Mark Wilson:
About The Cochrane Collaboration: Cochrane exists so that healthcare decisions get better.
Ema Kufel
Co-Founder, CEO of Prosoma
Co-Founder/CEO, Ema is an (MSc) Marketing Communications graduate and an expert in healthcare communications. Ema has vast experience in managing projects developing digital strategies within the National Health Service and the Department of Health in the UK. She is passionate about healthcare and innovation, key components of Prosoma.
Follow Ema Kufel:
About Prosoma: At Prosoma, we design world-leading digital therapeutics solutions for Oncology.
Barry Shrier
Co-Founder & CEO of The Health-Tech Innovation LABS
Barry Shrier is Founder and CEO of Health-tech Innovation LABS, Barry is a serial entrepreneur with a history of successful exits .
Follow Barry Shrier:
About GIANT Health Events, The Health-Tech Innovation LABS: The Health-Tech Innovation LABS (HTI-LABS) are a group of businesses that improve the healthcare sector.
Ronan Cunningham
Founder and Chief Executive Officer of BrainWaveBank
Ronan has more than 20 years of experience in advanced engineering and product development. He was one of the founding members of ATA Engineering, an award-winning San Diego-based engineering company specializing in development of innovative hardware and software technologies for the aerospace and defence industries. His roles have included Director of Business Development and Director of New Technology Development. He is an Entrepreneur-in-Residence with the Northern Ireland Science Park. His expertise is in early stage technology development, innovation strategy, and technology commercialisation. He holds an MS in Aeronautics and Astronautics from MIT.
Follow Ronan Cunningham:
About BrainWaveBank, Cumulus Neuroscience: BrainWaveBank makes it possible to measure and track brain activity and cognitive performance for anyone, anytime, anywhere.
Alexandra Hussenot
Founder & CEO of Immersionn
Alexandra is the founder of Immersionn, the world’s first VR Discovery Engine and she is also the UK lead for ‘Women in Immersive Technologies’, a community of 1000 members that aims to empower European women working in XR. She is also 1 in 10 members of the UK5G Creative Industries working group reporting the department in charge of Digital, Medias, Culture and Sport (DCMS). Prior to this, Alexandra pursued an international business career at insurance firm, Allianz, managing an £80M global business. She has also worked all over Europe during her 11 years at Sony Ericsson (now Sony Mobile) and has solid experience designing and launching software and service products, particularly covering user experience design and continuous improvements. She also lead large scale operations for mobile phone repairs and remanufacturing.
Follow Alexandra Hussenot:
About Immersionn: Immersionn is a content discovery company. We allow people to discover VR content they would never find
Colin Story
Co-Founder & CEO of OxSonics Therapeutics
Colin Story brings over 20 years of medical technology and life sciences industrial experience, the majority held in commercial roles. After graduating with a BSc degree in Biological Sciences and a PhD in Molecular Biology he started his career at Amersham plc (now GE Healthcare) in 1997. Initially he held Product Development and Project Management roles in R&D and then latterly held a commercial role where he managed a £20m product portfolio. In 2005 he joined Isis Innovation Ltd, where he initiated, led and concluded a range of multi-£m transactions. In 2008 he went on to recruit and direct a Business Development team that managed over 200 medical science innovations emanating from Oxford University. In 2011 he joined OrganOx Ltd as Operations Director where he handled all operational and contractual aspects of the business that saw the company take a class III medical device from prototype into, and successfully through, first in man clinical trials. In January 2014 he became Co-Founder, Executive Director and the Chief Executive Officer of OxSonics® Ltd.
Follow Colin Story:
About OrthoSon, OxSonics Therapeutics: OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Christoph Lippuner
Co-founder & CEO of Heydoc
Christoph Lippuner is Co-Founder at Heydoc.
Follow Christoph Lippuner:
About Heydoc: The integrated clinical system for managing your patients’ medical data and admin tasks.
James Roberts
CEO/Founder of mOm Incubators
Follow James Roberts:
About mOm Incubators, Royal Academy of Engineering, The Royal Society for the encouragement of Arts, Manufactures and Commerce (RSA): mOm is an inexpensive, electronically controlled, inflatable incubator constructed to decrease the number of premature child deaths.
Peter Schwabach
Chief Executive Officer of Innovision
Follow Peter Schwabach:
About Innovision: Innovision is a brain injury diagnostic software company that is able for the first time to accurately detect traumatic brain injuries.
Simos Kedikoglou
Chief Executive Officer of Impulse Dynamics
Simos Kedikoglou is the CEO of Impulse Dynamics since 2013 and serves on the Company’s Board of Directors.He was previously CEO of MedInvest, an Israeli Medical Technology Incubator overseeing 10 portfolio companies with responsibility for their clinical and commercial strategy, technology development and debt and equity financing. He has also served as Corporate Vice President of Business Development for Boston Scientific responsible for acquisitions, licensing and distribution deals in the US, Europe and Asia and an Associate Partner with McKinsey & Company in the US advising clients on acquisitions in pharmaceuticals and medical devices. Simos holds a Medical Degree from the University of Athens, Greece, an MBA with distinction from Harvard Business School as well as a Master’s in Public Health from Harvard University, and he is a CFA Charterholder.
Follow Simos Kedikoglou:
About Impulse Dynamics: Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF).
Harry Destecroix
Founder and CEO of Ziylo
Follow Harry Destecroix:
About Ziylo: Ziylo has developed Biomimetic Glucose Binding Molecules (GBM) for Continuous Glucose Monitors (CGM) & Glucose Responsive Insulins (GRI)
George Frodsham
Founder & CEO of MediSieve
George Frodsham founded MediSieve after being awarded his PhD in biochemical engineering from University College London (UCL), during which he developed the magnetic blood filter. As well as being a physicist and engineer, George is an entrepreneur. George was awarded a BBSRC Enterprise Fellowship from the Royal Society of Edinburgh in 2014. Since 1996, only 180 individuals have benefited from this highly competitive and prestigious programme. George has also completed the Entrepreneurship Summer School programme at the London Business School. This equipped him to research target markets and industries and turn his visions into viable businesses.
Follow George Frodsham:
About MediSieve: MediSieve is a therapeutics company developing a platform technology for the treatment of blood-borne diseases.
Kit Latham
CEO of Drfocused
Kit Latham is an Emergency Medicine doctor with a passion for entrepreneurship and improving the lives and development of health professionals.
Follow Kit Latham:
About Credentially, Drfocused: Drfocused creates clinician-centred digital solutions improve the working lives of doctors.
Duncan McWilliam
Founder & CEO of VitaeVR
Duncan McWilliam is the founder and CEO of VitaeVR and Outpost VFX.
Follow Duncan McWilliam:
About VitaeVR: Medical devices for early diagnosis of cognitive disease
Olga Kubassova
Chief Executive Officer of IAG, Image Analysis Group
Olga Kubassova is the Founder and CEO at IAG, mage Analysis Group. Mathematician with 10+ years expertise in actively managing innovation in life science companies, asset positioning, strategy and capital rising. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.
Follow Olga Kubassova:
About Analytics Ventures, Bio Capital Impact Fund, European Commission, IAG, Image Analysis Group: IAG, imaging expert company helps to accelerate novel drug development by using the right analytical tools and modern trial infrastructure.
Ozgur Tuncer
CEO & Executive Director of Stablepharma Ltd
Ozgur Tuncer CEO & Executive Director – two decades of experience in the biopharmaceutical industry including working for blue chip companies such as Pfizer, IQVIA and Pharmacia. Most recently, he was Global Vice President in IQVIA, and strategic adviser to life sciences investors. In addition to his role in Stablepharma, Özgür is an Investment Partner with Ascension Ventures.
Follow Ozgur Tuncer:
About Stablepharma Ltd: An innovative Biotech, developing a wide range of reformulated thermostable and fridge free StablevaX vaccines
Lukas Lange
CEO and Co-Founder of Probably Genetic
Follow Lukas Lange:
About Probably Genetic: Probably Genetic helps rare genetic disease patients.
Caroline Barelle
Chief Executive Officer and founder of Elasmogen
With postgraduate qualifications in both business and science, Caroline has a strong commercial, bio-partnering and biologics drug discovery/development background. For over 4 years she has successfully led teams at Wyeth Inc and subsequently Pfizer Inc in Global Bio-therapeutic Technologies progressing early platform technologies to late stage clinical development. Prior to this she was Alliance and Programs Manager at Haptogen Ltd and a key part of the acquisition team that successfully exited the business to Wyeth Inc. She has been awarded a prestigious Royal Society of Edinburgh commercialisation Fellowship and is a doctoral graduate from the University of Aberdeen in Biochemistry.
Follow Caroline Barelle:
About Elasmogen, Queen’s University Belfast: Elasmogen is a precision biologics drug discovery company that develops soloMERs.
Kitty Liao
Founder & CEO of Ideabatic
Royal Academy of Engineering 2018 Enterprise Fellow, Ambassador at THE Port Association, Switzerland. Ten years experience in multi-disciplinary system design and R&D, including low temperature systems, superconducting cavity diagnostics systems and design for low-resource settings.
Follow Kitty Liao:
About Ideabatic: Ideabatic is solving the most challenging humanitarian problems by delivering innovative solutions and devices.
Ibraheem Mahmood
CEO of DrugDev
Ibraheem Mahmood is the president and CEO of DrugDev.
Follow Ibraheem Mahmood:
About AMO Pharma, DrugDev: DrugDev is a cloud technology based solutions that enable better clinical trials.
Elliot Street
Co-Founder & CEO of Inovus Medical
Elliot studied medicine at the University of Manchester before completing his foundation training at the Oxford University Hospitals. Alongside his clinical commitments, he retains an active role in product development, bridging the gap between clinician and designer as well as running Inovus’ sales and marketing operations.
Follow Elliot Street:
About Inovus Medical, NHS England: The perfect package for any general surgical trainees or residents.
Christophe Berthoux
Chief Executive Officer of NAMSA
Follow Christophe Berthoux:
About NAMSA: NAMSA is a medical research organization speeding product development for medical devices, IVDs, regenerative medicine.
Joanna Gould
CEO of VisusNano
Joanna obtained her PhD in developmental Neuroscience at the University of Southampton. After her MRes Joanna had a career change and went into corporate banking at Bank of America before deciding to come back to science. Joanna has also worked in research and development at an SME.
Follow Joanna Gould:
About VisusNano: Revolutionising Treatment for Cataracts
Manuel Llobet
CEO of Allergy Therapeutics
Manuel Llobet joined the Company in September 2009 following the successful refinancing by Azure Ventures Limited. Prior to this appointment, Manuel was the Principal Consultant for Biohealth LLC and CEO of International Operations of the Weinstein family’s group of companies. Mr Llobet was responsible for international development of the Weinstein family’s group of pharmaceutical companies in 20 countries. Mr Llobet has over ten years experience working in the pharmaceutical industry, primarily in South America and has served as Executive Director of Coporación Drokasa where he was responsible for a US$25 million AAA-rated bond issue to finance the group’s expansion plans; CEO of Laboratorios Andrómaco where he led the Company to an IPO on the Santiago Stock Exchange; and Business Development Manager for Laboratorio Chile. Mr Llobet participated in the Executive Program at the Graduate Business School of Stanford University and has an MBA from IESE, Universidad de Navarra, Barcelona. Mr Llobet also has degrees in Industrial Business Management and Chemical Engineering from Universitat Ramon Llull, Barcelona.
Follow Manuel Llobet:
About Allergy Therapeutics: Allergy Therapeutics (AT) is a European-based speciality pharmaceutical company focused upon the treatment and prevention of allergy.
Clive Morris
President & Chief Executive Officer of Inivata
Follow Clive Morris:
About Inivata: Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis.
Javier Gonzalez-Zabaleta
Founder & CEO of Medimsight
Javier Gonzalez-Zabaleta was the main designer of the cloud model to bring worldwide medical imaging artificial intelligence solutions accessible to everyone. As one of the pioneers in this space, he has achieved a good experience in both market space and the technology. During last 10 years, he focused at the same time in business development, including direct communication with clinicians, and the understanding of the clinical trials market. Always open to talk, partnering and sharing knowledge. At the university, he studied computer science before made a master degree in computer vision making research in areas like multiple sclerosis and Alzheimer disease. Following his dream, empowering researchers and building super doctors, he has lived in Ponferrada, Madrid and now in London.
Follow Javier Gonzalez-Zabaleta:
About FundRx, Medimsight: Medical image triage and biomarkers analysis for precision medicine.
Anna Stoilova
Co-founder & CEO of Dual Good Health
Follow Anna Stoilova:
About Dual Good Health, TIKI: Using virtual reality to train more people how to save lives
Peter Donnelly
Chief Executive Officer of Genomics
Peter Donnelly is Director of the Wellcome Trust Centre for Human Genetics and Professor of Statistical Science at the University of Oxford, and a founder and director of Genomics plc, a fast-growing company in the genome analytics space. He has played a leading role in many of the major projects and developments at the interface between genetics, healthcare, and clinical medicine, including the HapMap project, the Wellcome Trust Case Control consortia, and WGS500, one of the studies pioneering whole genome sequencing in clinical medicine.
Follow Peter Donnelly:
About Genomics, University of Oxford: Genomics plc aiming to lead the genomic transformation of healthcare.
Eric Mayes
CEO of Endomag
Dr Mayes has over 20 years’ experience in developing and leading materials technology companies. Prior to joining Endomag as CEO in 2010, Eric held executive positions in Cambridge Display Technology (CDT) and NanoMagnetics. He was named the Royal Society of Chemistry’s ‘Entrepreneur of the Year 2003’ for his founding role in NanoMagnetics. Eric is an advisor to the University of Texas at Austin’s ‘Texas Health Catalyst’ and the European Healthtech Translation Advisory Board (HealthtechTAB). A US-UK dual national, he holds a BSc in Physics from Arkansas State University and a PhD in Chemistry from the University of Bath. Eric is a Fellow of the Royal Society of Chemistry.
Follow Eric Mayes:
About Endomag: Endomag is a medical technology company devoted to improving breast cancer care through its magnetic sensing technologies.
Faii Ong
Founder and CEO of GyroGear
Faii Ong is the founder and CEO of GyroGear.
Follow Faii Ong:
About GyroGear: GyroGear is developing a wearable to help individuals with hand tremors.
Mary Kerr
CEO of NeRRe Therapeutics
Mary co-founded KaNDy Therapeutics in 2017 as a spin out from NeRRe Therapeutics. KaNDy was formed to ensure a single-minded focus in developing NT-814 as a novel and breakthrough treatment for symptoms of the menopause. Mary has held a range of senior leadership roles in the pharmaceutical industry having spent the majority of her career on the R&D/commercial interface in global strategy and regional operational roles, predominantly in the specialty and orphan space. She was a founding member of the executive team of ViiV Healthcare (the independent, HIV company that combines the HIV expertise of GSK, Pfizer Inc. and Shionogi) where she led, revitalised and grew the business throughout Europe. Mary was also previously Senior Vice President and Global Franchise Head at GSK. Mary also currently serves as CEO of NeRRe and is a non-executive independent director at Galapagos NV. Mary gained a PhD in Pharmacology at the University of Bradford, did post-doctoral research at the Michigan Cancer Foundation, Detroit and has an MBA from the University of Kingston.
Follow Mary Kerr:
About Galapagos, NeRRe Therapeutics: NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.
Damien McDonald
CEO of LivaNova
Damien McDonald is the Chief Executive Officer of LivaNova. Previously, Mr. McDonald served as Chief Operating Officer of LivaNova. Prior to that, he was Group Executive and Corporate Vice President at Danaher Corporation where he led a $1.5-billion group of dental consumables companies. Earlier in his tenure, he was Group President of Kerr where he and his team focused on building a strong research and development pipeline while improving operational performance utilizing the Danaher Business System. Additionally, Mr. McDonald previously led Zimmer’s spine division where he demonstrated his leadership skills, attracting a strong executive team that created a growth trajectory for the business unit. Earlier in his career, he worked with J&J’s Medical Device Franchises, including Ethicon, where he led marketing of the $2.5-billion medical device unit. Mr. McDonald earned an MBA at the Institute for Management Development (IMD) in Lausanne, Switzerland, along with a Master of Science in International Economics from the University of Wales, U.K. He also holds a Bachelor of Economics degree and Bachelor of Pharmacy degree, both from the University of Queensland, Australia. Mr. McDonald is a non-executive director of the regenerative medicine company Avita Medical (ASX:AVH).
Follow Damien McDonald:
About LivaNova: LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment.
Mike Karim
CEO and Co-founder of Oxford Endovascular
Over 20 years of international experience in medical devices including endovascular products. Leadership roles in general management, sales & marketing and mentoring. Success in fund raising, driving business growth in large corporations, SMEs and start ups, developing and bringing new products to market.
Follow Mike Karim:
About Oxford Endovascular: Oxford Endovascular are developing a novel treatment for treating brain aneurysms.
Alan Sutherland
Chief Executive Officer of Kind Consumer
Alan Sutherland is the CEO of Kind Consumer.
Follow Alan Sutherland:
About Dyson, Kind Consumer: Kind Consumer is a healthcare research and development company focused on inhalation technologies.
Nick Skaer
Founder and CEO of Orthox Ltd.
Nick Skaer has over 20 years experience in life science and materials research, and 10 years as a medtech CEO raising over £10m to fund development of FibroFix™ technology. In 2008 he founded Orthox with Prof. Oliver Kessler, securing a Translation Award from Wellcome Trust. Since then he has led the scientific and commercial programmes at Orthox, with further awards from the Technology Strategy Board, Wellcome Trust, and NIHR. Before this he was CSO, then CEO of Oxford Biomaterials from 2004 to 2009 where he developed the FibroFix™ technology and implemented the medical device programme. During this period he co-authored 5 patents, including the three assigned to Orthox, secured over £2 million in public grants and private investment and formed 3 spin out companies from Oxford Biomaterials to commercialise biomaterial technologies. Between 1992 and 2003 he studied Molecular Biology at the Universities of Oxford, Cambridge and Strasbourg France, where he obtained his PhD.
Follow Nick Skaer:
About Orthox Ltd.: Orthox develops tissue regenerative implants that address large injuries to cartilage tissues in which early osteoarthritis may be present.
Ann Kramer
CEO of The Electrospinning Company
Ann Kramer is CEO of The Electrospinning Company: a biomaterial platform company with applications in regenerative medicine and medical device markets.
Ann graduated from the University of Cambridge with a degree in Natural Sciences and joined ICI Agrochemicals. Over almost 20 years with ICI, Zeneca and Syngenta she gained experience across the business including in research, sales, business development and M&A, with roles in the UK, USA and Switzerland. She managed the development of genetically modified food business streams in fresh produce crops. Since 2006 she has worked in the SME sector in the UK as Head of Business development for Oxitec Ltd. (acquired by Intrexon in 2015), COO of Immunocore Ltd. and CEO of Biosyntha Ltd. She joined The Electrospinning Company as CEO in 2012.
Follow Ann Kramer:
About The Electrospinning Company: The Electrospinning Company is a provider of electrospun nanofibre innovations, developing solutions to industrial challenges.
Anna Perdrix Rosell
Co-Founder & Co-CEO of Sixfold Bioscience
Anna Perdrix Rosell is the Co-Founder & Co-CEO at Sixfold Bioscience.
Follow Anna Perdrix Rosell:
About Sixfold Bioscience: Sixfold Bioscience develops and researches on biotechnology advances for RNA therapies.
George Foot
Co-Founder & Co-CEO of Sixfold Bioscience
George Foot is the Co-Founder & Co-CEO at Sixfold Bioscience.
Follow George Foot:
About Sixfold Bioscience: Sixfold Bioscience develops and researches on biotechnology advances for RNA therapies.
